Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF
作者： Chris Takimoto , Russell Kruzelock
DOI: 10.1007/978-1-59745-215-1_15
关键词:
摘要: The advent of molecularly targeted therapies has fundamentally changed anticancer drug development. Advances in molecular oncology have altered scientific paradigms discovery, and preclinical early clinical In the current era, selective are now rationally designed to inhibit specific novel targets that well characterized at level. Inherent this approach new strategies include testing agents pharmacogenetically defined populations, analyzing profile tumors prior treatment, individualizing therapy for each unique patient. Examples promising future treating patients with colorectal cancer PI3K/Akt/mTOR signaling pathway antiangiogenic inhibition, name just two. This brief review discusses challenges changing related developing therapeutics age therapies.
springer.com
sci-hub.st 参考文章(46)
W. L. McGuire, G. C. Chamness, Studies on the Estrogen Receptor in Breast Cancer Advances in Experimental Medicine and Biology. ,vol. 36, pp. 113- 136 ,(1973) , 10.1007/978-1-4684-3237-4_7
Takehiko Sasazuki, Senji Shirasawa, Koji Okumura, Miharu Nishioka, Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells. Cancer Research. ,vol. 59, pp. 2445- 2450 ,(1999)
Daqing Wu, Chittam U Thakore, Ginger G Wescott, James A McCubrey, David M Terrian, Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene. ,vol. 23, pp. 8659- 8672 ,(2004) , 10.1038/SJ.ONC.1207900
BARNETT ROSENBERG, LORETTA VAN CAMP, THOMAS KRIGAS, Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode Nature. ,vol. 205, pp. 698- 699 ,(1965) , 10.1038/205698A0
L.C. Foukas, P.R. Shepherd, Phosphoinositide 3-kinase: the protein kinase that time forgot. Biochemical Society Transactions. ,vol. 32, pp. 330- 331 ,(2004) , 10.1042/BST0320330
Thomas Efferth, Manfred Volm, Pharmacogenetics for individualized cancer chemotherapy Pharmacology & Therapeutics. ,vol. 107, pp. 155- 176 ,(2005) , 10.1016/J.PHARMTHERA.2005.02.005
P. Workman, Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochemical Society Transactions. ,vol. 32, pp. 393- 396 ,(2004) , 10.1042/BST0320393
Nicholas C. Dracopoli, Pharmacogenomic applications in clinical drug development. Cancer Chemotherapy and Pharmacology. ,vol. 52, pp. 57- 60 ,(2003) , 10.1007/S00280-003-0594-Z
R. K. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science. ,vol. 307, pp. 58- 62 ,(2005) , 10.1126/SCIENCE.1104819
Bert Vogelstein, Kenneth W Kinzler, Cancer genes and the pathways they control. Nature Medicine. ,vol. 10, pp. 789- 799 ,(2004) , 10.1038/NM1087